Intermediates of Eribulin Mesylate

Views: 131 Author: Site Editor Publish Time: 2020-12-28 Origin: Site

Eribulin is a chemotherapy drug. Its full name is eribulin mesylate. Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors 2.

Structure

C40H59NO11

Monoisotopic Weight: 729.89

Chemical Formula: C40H59NO11

Mechanism of Action

Eribulin inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into nonproductive aggregates. Eribulin exerts its effects via a tubulin-based antimitotic mechanism leading to G2/M cell-cycle block, disruption of mitotic spindles, and, ultimately, apoptotic cell death after prolonged mitotic blockage.

Key synthesis steps

key synthesis of Eribulin 1

key synthesis of Eribulin 2

key synthesis of Eribulin 3

key synthesis of Eribulin 4

Main intermediates of Eribulin Mesylate we can commercial supply

CAS#157322-83-3

Fragment A;

Methyl 2-((2R,4aS,6S,7R,8S,8aS)-7,8-bis((tert-butyldimethylsilyl)oxy)-6-((S,E)-1-((tert-butyldimethylsilyl)oxy)-3-iodoallyl)octahydropyrano[3,2-b]pyran-2-yl)acetate

CAS#157322-47-9

Fragment B;
[2S-[2alpha,5beta(3S*,5S*)]]-2,2-Dimethylpropanoic acid 3-[tetrahydro-5-(3-hydroxy-6-iodo-5-methyl-6-heptenyl)-4-methylene-2-furanyl]propyl ester